2 Hebrew University scientists awarded W...(ob Grunbaum Professor of Medical Science...),Health
Navigation Links
2 Hebrew University scientists awarded Wolf Prizes
Date:1/9/2008
ob Grunbaum Professor of Medical Sciences.
Cedar and Razin have both received the Israel Prize and are members of the European Molecular Biology Organization (EMBO) and the Human Genome Organization (HUGO).
The Israel-based Wolf Foundation was established by the late German-born inventor, diplomat and philanthropist, Dr. Ricardo Wolf. Five annual Wolf Prizes, of $100,000 in each area, have been awarded since 1978 to outstanding scientists and artists ''for achievements in the interest of mankind and friendly relations among peoples, irrespective of nationality, race, color, religion, sex or political view.'' To date, a total of 241 scientists and artists from 22 countries have been honored.
The prize will be presented by the president of Israel, Shimon Peres, at a special ceremony at the Knesset in Jerusalem on Sunday, May 25.
'/>"/>
| Contact: Jerry Barach jerryb@savion.huji.ac.il 972-258-82904 The Hebrew University of Jerusalem Source:Eurekalert |
Related medicine news :
1. NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired
2. Rockefeller Universitys Center for Clinical and Translational Science funds pilot studies
3. Presidential Candidate and Former Arkansas Governor Mike Huckabee to Be Keynote Speaker for Hope International Universitys Celebrate Hope Dinner at Disneyland(R) Hotel
4. University Hospitals Chief Executive Officer Extends Contract
5. Delta Dental of Illinois Announces Major Gift to University of Illinois at Chicago College of Dentistry
6. Royalty Pharma Acquires a Portion of Northwestern Universitys Royalty Interest in Lyrica(R) for $700 Million
7. Study investigates cannabis use among university students
8. Boston University Medical Center researcher honored
9. Brooks and the University of Florida Reach Research Agreement
10. University of British Columbia Research Shows Health Benefits of GameBike (TM)
11. Loma Linda University to Dedicate Proton Treatment Center to Cancer Therapy Pioneer James M. Slater, M.D.
Post Your Comments:
Related Image:
 2 Hebrew University scientists awarded Wolf Prizes |
(Date:11/25/2009)...survivors of testicular cancer who were treated wi...de effects, including neurological side effects an...eated with chemotherapy, according to a new study ...e National Cancer Institute . , Marianne Brydy, ...versity Hospital, in Bergen, Norway, and colleague...
(Date:11/25/2009)...lready used to fight rheumatoid arthritis, could h... , WEDNESDAY, Nov. 25 (HealthDay News) -- A dr...nd rheumatoid arthritis now also shows some promis...diabetes. , The drug, rituximab (Rituxan), help...in, even though the disease had destroyed some of ...
(Date:11/25/2009)...ORK,Nov.25/PRNewswire/-- MISSIONSkincare ®isp...orSt.Jude.AspartofGNC,sannualSt.Jude ThanksandGivi...kincare,s new SUPER-C(TM)LipBalm willbedonatedto...ytomakea$1,$5or$10donationatcheckoutatoneoftheir5,...than$1millionforSt.Judeduringtheir2009 ThanksandGi...
(Date:11/25/2009)...s behavior problems that can occur in children wit...h a treatment plan that includes medication combin... according to Yale University researchers and thei...issue of the Journal of the American Academy of C...ducted by the National Institute of Mental Health ...
(Date:11/25/2009)... BioSpace.com, the premier resource f...the third edition of the BioForest™ Hotbed C...nglewood, CO (Vocus) November 25, 2009 -- BioSpace...s and information, unveiled the third edition of t... , , , ,This regional campaign is a promotional e...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2[0] News brief: Long-term testicular cancer survivors at high risk for neurological side effects[0] Type 1 Diabetes May Have a New Foe[2] MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R)[0] Parent training key to improved treatment of behavior problems in children with autism[1] BioSpace Showcases Leading Life-Science Companies in the Northwest
...ull House and,Senate poised to vote on the Preside...horization bill, a five-year, $50 billion initiati...rldwide, Congress must address,the critical HIV pr... nearly two million more,people have access to ant...
...LY AGGRESSIVE VACCINATION SCHEDULE TO,COMBAT RISIN...children who,regressed into autism after receiving...vernment health officials may at last be catching ...nference call held earlier in March,bringing toget...
...tinue the habit after initial coil treatment surge...- Smokers with a brain aneurysm who are treated wi...tients to develop another aneurysm, according to a...the groin and then threaded to the affected area o...
...w medications longer, study finds , , FRID...second-generation antipsychotics are no better tha...pisode of schizophrenia, a new study finds. , Howe... we compared newer drugs to older drugs, we found ...
... T. Clark, Chief,Executive Officer and President o...eutical Research and Manufacturers of America (PhR...g. Also elected were AstraZeneca Chief,Executive O...asurer., In addition, PhRMA announced that Takeda...
...n German . , Boxing is possibly less dangerous ... amateurs. However, conclusive statements on the l...ssional boxers such as Muhammad Ali contracted the...il more extensive studies of both amateur and prof...
Other Medicine News:Health News:Will Congress Do More for HIV Prevention? 2Health News:Will Congress Do More for HIV Prevention? 3Health News:Will Congress Do More for HIV Prevention? 4Health News:MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk 2Health News:Smokers at Increased Risk of Aneurysm Recurrence 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Richard T. Clark Elected PhRMA Board Chairman 2Health News:Richard T. Clark Elected PhRMA Board Chairman 3Health News:Richard T. Clark Elected PhRMA Board Chairman 4Health News:Richard T. Clark Elected PhRMA Board Chairman 5Health News:How dangerous is boxing for the brain? 2Will Congress Do More for HIV Prevention?MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at RiskSmokers at Increased Risk of Aneurysm RecurrenceNew Drugs No Better Than Older Ones for SchizophreniaRichard T. Clark Elected PhRMA Board ChairmanHow dangerous is boxing for the brain?
(Date:11/24/2009)...,, IRVINE,Calif.,Nov.24/PRNewswire-FirstCall...llyinvasivetreatmentsforaorticdisorders,announcedt...oceedingsin,thepatentinfringementlawsuitbroughtaga...heUnitedStatesDistrictCourtinIndianapolis,Indiana....ectwhiletheUnitedStatesPatentandTrademarkOffice(US...
(Date:11/24/2009)...,, WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNew...heU.S.FoodandDrugAdministration(FDA)hasacceptedfor...mgAricept®(donepezilHClextendedrelease)tablet...se(AD).Thisnewhigherdoseformulationcontains23mgofd...thadeliverysystemthatallowsforgradualreleaseofthed...
(Date:11/24/2009)...,, STAMFORD,Conn.,Nov.24/PRNewswire/--Zargis...E )andaspin-offfromSiemensCorporateResearch(NYSE: ...sfeaturedontheNovember24,2009episodeofCBS, TheEarl...PopularScience magazine,reviewedfivewinningproduct...,, TheEarlyShow isawidely-viewedtelevisionmorn...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 1Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 2Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 1Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 1Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 3Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 4...INESS WIRE)--Apr 16, 2007 - Amgen,(Nasdaq:AMGN) to...e-blind, placebo-controlled Phase 3 study evaluati...tin alfa) for the,treatment of anemia in patients ...adiotherapy ("the 103 study"). Aranesp is not,appr... These,results were presented in an oral session a...
...primary endpoint not met; plausibly,confounded by ...TUX,-, NEW YORK, April 16, 2007 /PRNewswire-FirstC...yers Squibb Company today,announced detailed resul... multi-center Phase III trial - comparing ERBITUX(... in patients with,metastatic colorectal cancer (mC...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,MeetingRandomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients
Sophia Vest V-654
Gabrielle Vest V-650
Female Mini-VEST, Front Closure, X-Firm
Male Support Brief
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |